Invasive Pneumococcal Disease (IPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Invasive Pneumococcal Disease (IPD) Market Outlook

Thelansis’s “Invasive Pneumococcal Disease (IPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Pneumococcal Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Invasive Pneumococcal Disease (IPD) Overview

Invasive Pneumococcal Disease (IPD) is defined as an infection confirmed by the isolation of Streptococcus pneumoniae from a normally sterile site (eg, blood, cerebrospinal fluid, and pleural, joint, or peritoneal fluid but not sputum). Children with pneumococcal infection often present with non-specific symptoms and signs including isolated fever. Certain populations of children are at increased risk of IPD. Children at particularly high risk are those with antibody deficiencies, such as X-linked (Bruton's) agammaglobulinemia, anatomic or functional asplenia, sickle cell disease, HIV infection, and those with cochlear implants or CSF leak. Children with other chronic illnesses (eg, cardiac, pulmonary, or renal disease and diabetes mellitus) and those receiving chemotherapy or steroids are also at risk. Children in daycare from an early age also have a higher incidence of IPD. Around 10–20% of children with pneumococcal meningitis have underlying comorbidity. The manifestations of IPD are; Bacteremia, Pneumonia, Meningitis, Cellulitis, Sinusitis, Septic arthritis, Peritonitis, Otitis media, and Others. Bacteremia and pneumonia were most common and the pneumonia patients by definition were bacteremic. Otherwise, meningitis was the most common manifestation of IPD (4.9%) while endocarditis/pericarditis was the least common (<1%).

• The incidence of Invasive Pneumococcal Disease (IPD) in any population is affected by geographic location, time of year, serotype prevalence, age, comorbidities, and vaccination status. The highest incidence of the invasive pneumococcal disease occurs in adults ≥65 years of age, in children <2 years of age, and in those with certain underlying conditions, such as HIV infection.
• The incidence of invasive pneumococcal disease in individuals ≥65 years of age was 36.4 cases per 100,000 population and, in infants <1 year, the incidence was 34.2 cases per 100,000 population, compared with 3.8 cases per 100,000 population in individuals between 18 and 34 years of age.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: